Porsolt is proud to announce the renewal of its Good Laboratory Practice (GLP) compliance, following a recent external audit by the French authorities (ANSM Agence nationale de sécurité du médicament et des produits de santé). This uniquely places Porsolt in the preclinical CRO market, recognizes the high standards of work, and confirms its scientists are well versed and trained in GLP guidelines, where their experience and approach is extremely valuable for early stage research and mandatory GLP studies.
Porsolt first obtained GLP compliance over 20 years ago, and has maintained this status in every subsequent bi-annual inspection. The quality of preclinical results is crucial for successful drug screening and development. Regulatory authorities require later stage pre-clinical studies to be performed under GLP guidelines, including safety and toxicology studies.